A Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Orally-administered NGP 555 in Healthy Young Volunteers

Trial Profile

A Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Orally-administered NGP 555 in Healthy Young Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Jan 2017

At a glance

  • Drugs NGP 555 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Sponsors NeuroGenetic Pharmaceuticals
  • Most Recent Events

    • 09 Jan 2017 Results published in the NeuroGenetic Pharmaceuticals Media Release
    • 12 Jan 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 26 Aug 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top